Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Michigan
Clinical trial register · United States · industry-sponsored

Clinical Trials in Michigan, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
California 151 Florida 150 Arizona 96 Georgia 89 Illinois 70
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Janssen Research & Development, LLC41 Eli Lilly and Company40 AbbVie35 Merck Sharp & Dohme LLC34 Clear sponsor filter
State
California151 Florida150 Arizona96 Georgia89 Illinois70
All 44 states
Target enrolment
to

Trials with a site in Michigan

40 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
111
California, Florida, Georgia, Michigan
2026-10
Not yet open
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
DrugLY4405094
Eli Lilly and Company
Phase 1
68
California, Florida, Georgia, Michigan
2026-09
Not yet open
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
NCT07787169Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
DrugLY4405094
Eli Lilly and Company
Phase 1
179
California, Florida, Georgia, Michigan
2026-09
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Michigan, Missouri, North Carolina, Texas
2026-08-11
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
252
California, Florida, Idaho, Massachusetts, Michigan, Nevada, Pennsylvania, Utah
2026-06-01
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370Alzheimer Disease
Eli Lilly and Company
Phase 1
30
California, Florida, Michigan
2026-05-21
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
DrugLY4005130
Eli Lilly and Company
Phase 2
60
California, Florida, Massachusetts, Michigan, New Hampshire, Texas, Utah
2026-04-14
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Active, closed
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
NCT07258836Neoplasms, Healthy
Eli Lilly and Company
Phase 1
41
Connecticut, Massachusetts, Michigan, New York
2025-12-22
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
DrugBrenipatide
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Active, closed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093Obesity, Overweight, Chronic Low Back Pain (CLBP)
DrugRetatrutide
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400Parkinson Disease
Eli Lilly and Company
Phase 1
127
California, Florida, Michigan, Texas, Washington
2025-02-18
Recruiting
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768Alzheimer Disease, Healthy
Eli Lilly and Company
Phase 1
128
California, Florida, Georgia, Michigan, New Jersey, North Carolina
2024-10-29
Active, closed
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706Glioma
DrugsAbemaciclib·Temozolomide
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Cetuximab·Irinotecan·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah
2024-05-20
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
450
California, Colorado, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2024-04-26
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugsDonanemab·Dexamethasone
Eli Lilly and Company
Phase 3
1,175
Arizona, California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Rhode Island
2023-02-28
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751Non Small Cell Lung Cancer, Breast Cancer
DrugsAnastrozole·Abemaciclib·Pembrolizumab
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
DrugsRamucirumab·Gemcitabine·Cisplatin
Eli Lilly and Company
Phase 2
309
Arizona, California, District of Columbia, Florida, Michigan, Missouri, Pennsylvania, Tennessee
2016-05-19
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
669
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2014-07-22
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/michigan

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Michigan that also match the filters currently applied.

How many clinical trials are recruiting in Michigan?

22 of the 40 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Michigan), 40 studies
PhaseStudiesRecruitingShare
Phase 1161140%
Phase 315437.5%
Phase 29722.5%

Most active sponsors

Lead sponsors with the most studies (Michigan)
Lead sponsorStudiesRecruiting
Eli Lilly and Company4022
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.